Silexion Therapeutics Corp Ordinary Shares
$0.44
Market Cap
$2.42M
Shares Outstanding
5.6M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Aug 16, 2024
Round Lot
100
Locale
US
Day Open
$0.39
Day High
$0.45
Day Low
$0.38
Volume
27.81M
VWAP
$0.42
Prev Close
$0.38
Transactions
--
Acc. Volume
--
Silexion Therapeutics Corp is a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for cancers driven by mutations in the mutations in the Kirsten rat sarcoma viral oncogene homolog (KRAS). Its proprietary technology is designed to prompt tumor cells to degrade the messenger RNA (mRNA) that bridges the oncogene and the cellular protein synthesis machinery, utilizing small interfering RNA (siRNA) constructs that are chemically modified to enhance stability and cellular uptake while maintaining biological activity that interferes with the mRNA function. Its product candidate, SIL204, is a second-generation siRNA engineered to suppress the production of mutated KRAS proteins.
Silexion Therapeutics Corp Ordinary Shares (SLXN) closed the 2026-09-18 session at $0.44, up 14.61% versus the previous close (+0.06). The stock opened at $0.39 and traded between $0.38 and $0.45 during that session. Session trading volume was 27.8M shares. The volume-weighted average price (VWAP) is $0.42.
Silexion Therapeutics Corp is a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for cancers driven by mutations in the mutations in the Kirsten rat sarcoma viral oncogene homolog (KRAS). Its proprietary technology is designed to prompt tumor cells to degrade the messenger RNA (mRNA) that bridges the oncogene and the cellular protein synthesis machinery, utilizing small interfering RNA (siRNA) constructs that are chemically modified to enhance stability and cellular uptake while maintaining biological activity that interferes with the mRNA function. Its product candidate, SIL204, is a second-generation siRNA engineered to suppress the production of mutated KRAS proteins.
Silexion Therapeutics Corp Ordinary Shares has a market capitalization of $2.4 million. The company operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry classification. SLXN is listed on the XNAS exchange. The company employs approximately 13 people. Silexion Therapeutics Corp Ordinary Shares is headquartered in RAMAT GAN, L3. The recorded listing date is 2024-08-16.
On this page you can find market SLXN stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.